The Vigabatrin REMS Program is called for by the FDA to ensure notified risk-benefit decisions prior to launching treatment, and to make sure suitable use of vigabatrin while people are treated. When vision loss will happen, it is not feasible for your health care company to know.
It is suggested that your healthcare provider test your (or your youngster's) vision before or within 4 weeks after starting SABRIL and at least every 3 months throughout treatment up until SABRIL is quit. Tell your healthcare provider if you or your youngster have any side effect that bothers you or that does not go away.
If you are expecting or mean to obtain expecting, inform your healthcare company. If vision screening can not be done, your healthcare provider may proceed recommending SABRIL, but will certainly not be able to look for any kind of vision loss. If vision tests are refrained on a regular basis, your healthcare provider might quit prescribing SABRIL for you (or your child).